Literature DB >> 21739367

[Neuropathic and tumour-induced headache: Therapeutic options].

A Wagner1, J A Blunk, J Benrath.   

Abstract

Cancer pain in the field of otolaryngology can be effectively alleviated. Only very few questions regarding the patient's history of pain are required to understand the type of pain being dealt with and to be able to make the correct selection of analgetic agents. It is particularly important to treat tumor breakthrough pain appropriately, for which a sufficient number of therapeutic agents are available. The present article comments on the various possibilities of specific drugs and interventional therapeutic approaches, as well as their specific characteristics within the field of otolaryngology, supplemented with various tricks for their practical application. Using these basic rules, most problems can be identified and specific treatments optimized. The progression of cancer pain may show wide dynamic ranges, and the therapeutic approach should always be adjusted to the current situation. Palliative care of a cancer patient may be particularly challenging in that, not only the treatment of pain, but also the treatment of respiratory distress is of key importance.

Entities:  

Mesh:

Year:  2011        PMID: 21739367     DOI: 10.1007/s00106-011-2269-0

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  17 in total

1.  Fentanyl for breakthrough cancer pain--what's new?

Authors:  Nora M Hagelberg; Klaus T Olkkola
Journal:  Pain       Date:  2010-12       Impact factor: 6.961

Review 2.  Intravenous morphine for management of cancer pain.

Authors:  Sebastiano Mercadante
Journal:  Lancet Oncol       Date:  2010-05       Impact factor: 41.316

Review 3.  Breakthrough pain: progress in management.

Authors:  Dominique A Lossignol; Cristina Dumitrescu
Journal:  Curr Opin Oncol       Date:  2010-07       Impact factor: 3.645

4.  The impact of a comprehensive evaluation in the management of cancer pain.

Authors:  Gilbert R Gonzales; Kathryn J Elliott; Russell K Portenoy; Kathleen M Foley
Journal:  Pain       Date:  1991-11       Impact factor: 6.961

Review 5.  Oral mucositis: the new paradigms.

Authors:  Douglas E Peterson; Rajesh V Lalla
Journal:  Curr Opin Oncol       Date:  2010-07       Impact factor: 3.645

Review 6.  Opioids for cancer pain: the challenge of optimizing treatment.

Authors:  Gérard E Plante; Theodore B VanItallie
Journal:  Metabolism       Date:  2010-10       Impact factor: 8.694

Review 7.  Neuropathic pain in cancer patients: mechanisms, syndromes, and clinical controversies.

Authors:  L A Martin; N A Hagen
Journal:  J Pain Symptom Manage       Date:  1997-08       Impact factor: 3.612

8.  Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study.

Authors:  Detlev F J Zech; Stefan Grond; John Lynch; Dagmar Hertel; Klaus A Lehmann
Journal:  Pain       Date:  1995-10       Impact factor: 6.961

Review 9.  Under-treatment of cancer pain.

Authors:  Alysa Fairchild
Journal:  Curr Opin Support Palliat Care       Date:  2010-03       Impact factor: 2.302

Review 10.  The role of fentanyl in cancer-related pain.

Authors:  Eric Prommer
Journal:  J Palliat Med       Date:  2009-10       Impact factor: 2.947

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.